Osiris Therapeutics (OSIR) to Receive $750K from Prochymal Phase II Completion
Tweet Send to a Friend
Osiris Therapeutics, Inc. (NASDAQ: OSIR) today announced that it has achieved a $750,000 milestone payment from the Juvenile Diabetes Research ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
